Please assess the completion status of the following clinical trial:

Trial Title: Laser Therapy Versus Narrow Band Ultraviolet B for the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ranged from 18-35 years.~* Skin type III and IV.~* Mild to moderate facial acne.~Exclusion Criteria:~* Treatment with oral retinoid within past 1 year.~* Treatment with other acne treatment within past 3 months.~* History of treatment with systemic and topical antibiotics for acne vulgaris within the last 1 month.~* Treatment with oral isotretinoin within the last 6 months.~* Participants received radiotherapy or chemotherapy.~* Any history of photosensitivity.~* Chemical peels during the previous 4 weeks.~* Seizures,~* Pregnancy~* Use of oral contraceptives.~* Breastfeeding .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group 1 (Type: EXPERIMENTAL): Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
- Experimental group 2 (Type: EXPERIMENTAL): Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
- Control group (Type: ACTIVE_COMPARATOR): Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).